FindTrial
Sign In

RP-3500 (camonsertib)

DRUG2 trials

Sponsors

Repare Therapeutics

Conditions

Advanced Solid TumorAdvanced Solid Tumor, Adult

Phase 1

Study of RP-3500, Camonsertib, in Advanced Solid Tumors
CompletedNCT04497116
Repare TherapeuticsAdvanced Solid Tumor
Start: 2020-07-22End: 2025-06-13Updated: 2025-10-21
Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors
TerminatedNCT04972110
Repare TherapeuticsAdvanced Solid Tumor, Adult
Start: 2021-07-21End: 2024-11-13Updated: 2025-10-30

Related Papers

Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b Results.
2026-01-21
Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response-Deficient Tumors.
2025-10-01
Data from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
2025-10-01
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
JNCI Journal of the National Cancer Institute2024-05-069 citations
Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500)
Journal of Medicinal Chemistry2024-02-0121 citations
Abstract B001: Identification of monoallelic <i>ATM</i> loss-of-function and homologous recombination deficiency (HRD) in high-grade ovarian tumor with prolonged response to camonsertib and low-dose gemcitabine combination therapy
Cancer Research2024-01-091 citations
Abstract B026: Detection and characterization of DDR reversion alterations in baseline tissue and plasma samples from patients enrolled in the TRESR and ATTACC Phase I clinical trials
Cancer Research2024-01-09
Abstract B025: Exceptional response to the ataxia telangiectasia and Rad3-related inhibitor (ATRi), camonsertib, in a patient with alternative lengthening of telomeres (ALT)-positive metastatic melanoma
Cancer Research2024-01-09
Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib
Clinical Cancer Research2023-12-115 citations
Abstract A123: Circulating tumor DNA (ctDNA) genomic and epigenomic profiling (GuardantINFINITY) for diagnosis of DNA damage repair (DDR) loss of function (LOF) and response monitoring in the TRESR and ATTACC trials
Molecular Cancer Therapeutics2023-12-011 citations
Abstract B045: Ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in combination with low dose gemcitabine in patients with solid tumors with DNA damage response (DDR) aberrations: Preclinical and Phase 1b results
Molecular Cancer Therapeutics2023-12-01
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.
2023-06-0567 citations
Abstract CT018: Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations
Cancer Research2023-04-147 citations
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial
BMC Cancer2023-02-2223 citations
ATR Inhibitor Camonsertib (RP-3500) Suppresses Early Stage Erythroblasts By Mediating Ferroptosis
Blood2022-11-157 citations
Abstract CT030: Genomic and pathologic determinants of response to RP-3500, an ataxia telangiectasia and Rad3-related inhibitor (ATRi), in patients (pts) with DNA damage repair (DDR) loss-of-function (LOF) mutant tumors in the Phase 1/2 TRESR trial
Cancer Research2022-06-1512 citations
Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116).
Journal of Clinical Oncology2022-06-014 citations
RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors.
2021-12-1569 citations
Abstract CC04-01: First-in-human biomarker-driven phase I TRESR trial of ataxia telangiectasia and Rad3-related inhibitor (ATRi) RP-3500 in patients (pts) with advanced solid tumors harboring synthetic lethal (SL) genomic alterations
Molecular Cancer Therapeutics2021-12-014 citations
Abstract P054: RP-3500: A novel, potent and selective ATR inhibitor that is effective in pre-clinical models as a monotherapy and in combination with PARP inhibitors
Molecular Cancer Therapeutics2021-12-01